Serina Therapeutics, Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q1 2018 to Q1 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Serina Therapeutics, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q1 2018 to Q1 2023.
- Serina Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending March 31, 2023 was -$3.29M, a 21.4% decline year-over-year.
- Serina Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending March 31, 2023 was -$11.1M, a 19.4% decline year-over-year.
- Serina Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$10.5M, a 19.2% decline from 2021.
- Serina Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$8.83M, a 19% increase from 2020.
- Serina Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2020 was -$10.9M, a 11.5% increase from 2019.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)